Ascofuranone demonstrated antitumor activity against FM3Amurine mammary carcinoma, implanted in the peritoneal cavity of syngeneic mice, C3H/He.It was more effective by treatment prior to implantation than by that after implantation. Treatment with ascofuranone also increased splenic cytotoxicity and phagocytic activity of host animal cells.
Moreover, ascofuranone induced inflammatory cells in the peritoneal cavity which are mainly composedof polymorpho-nuclear leukocytes and macrophages. These cells are more potent in cytotoxicity against FM3Acells than with resident peritoneal cells. The antitumor activity of ascofuranone was suppressed by ip administration of silica, just prior to tumor implantation. These results suggest that the prophylactic antitumor activity of ascofuranone is expressed through the activation of phagocytes.
Ascofuranone also suppressed pulmonary metastasis of B16 melanoma and Lewis lung carcinoma. Treatment after tumor implantaion failed to suppress the metastasis. Single treatment of ascofuranone 4 days prior to implantation decreased the metastasis of Lewis lung carcinoma but not that of B16, whereas single treatment of ascofuranone 24 hours prior to the tumor implantation decreased the metastasis of B16 but not that of Lewis lung carcinoma. 959 Ascofuranone is an isoprenoid antibiotic, originally isolated as a hypolipidemic substance from a culture broth of a phytopathogenic fungus, Ascochyta viciael\. We found it to have antitumor activity against murine experimental tumors2). The characteristics of the antitumor activity are that ascofuranone is effective by treatment prior to tumor implantation as well as by that after tumor implantation and that prophylactic antitumor activity needs no vaccination, suggesting that it directly stimulates nonspecific defense mechanisms against tumor development. In fact, treatment of normal mice with ascofuranone enlarges solid lymphoid organs2^and enhances spontaneous cytotoxic activity of splenocytes3).
In vitro study of ascofuranone4) shows that it is suppressive to lymphoid cell functions such as lectin-induced proliferative responses, interleukin 2 (IL-2) production and formation of IL-2 receptors. It also suppressed natural killer (NK) activity of splenocytes. In contrast, it stimulates glycolysis, interleukin 1 (IL-1) production and tumoricidal activity of macrophages. These results suggest that the antitumor activity of ascofuranone is expressed through activation of macrophages. This paper describes in vivo activation of phagocytes by ascofuranone in relation to the antitumor and antimetastatic activities. JULY 1988 
Materials and Methods

Mice
Six-week-old male C3H/Heand BDF1mice were purchased from Shizuoka Experimental Farm (Hamamatsu). Commercial pellet diet (CE-2, Clea, Japan, Ltd., Tokyo) and tap water were fed ad libitum. Mice were used no later than 10 weeks of age.
Ascofuranone
Purified ascofuranone was supplied by Chugai Pharmaceutical Co., Ltd. (Tokyo). For administration, ascofuranone was suspended in 0.5% Tween 80 in phosphate-buffered saline (PBS, 0.8 % NaCl, pH 7.4) with the aid of a Teflon homogenizer. Development of FM3AAscites Tumor FM3Acells, freshly isolated from the peritoneal cavity, were suspended in PBS and cell number was adjusted just before implantation. The tumor cells (105/mouse) were implanted in the peritoneal cavity. Antitumor activity was assessed by average survival time or the numberof survived mice.
Preparation of Splenocytes and Peritoneal Cells A single cell suspension of splenocytes, erythrocytes of which were ruptured by ammonium chloride, was prepared as described previously2). Splenocytes were suspended in RPMI-1640 medium supplemented with 50 jug/ml kanamycin and 5 x 10" 5 m 2-mercaptoethanol and 10 % fetal bovine serum (FBS). Peritoneal cells were collected with MEM supplemented with 5 x 10~5 m 2-mercaptoethanol and 50 u/ml heparin. The cells were washed twice with MEM and suspended in RPMI-1640medium. Cell type was determined morphologically under a microscope using May-GriinwaldGiemsa staining of cytocentrifuged cells.
Carbon Clearance Test Experiments were carried out as described by Gotoh et al.5\ Drawing ink (Rotring Werke, West Germany) was 10-fold diluted with PBS and 0.2 ml of the suspension was injected into mice via tail vein. Three minutes after the injection, 50 /4 of blood sample was removed from retro-orbital venous plexus by the use of capillary pipettes. The blood samples were immediately discharged into 3 ml of 0.5 %ammoniumchloride solution to disrupt erythrocytes and centrifuged at 3,000 rpm for 5 minutes. The amountof carbon in the supernatant was measuredby a spectrophotometer at 620 nm, using blood samples from the mice without carbon injection as a blank.
Cytotoxicity Assay
One million splenocytes or 4 x 105 peritoneal cells in 200 jul of mediumon a flat-bottomed microplate well were cultured for 4 hours with 1 x 104 51Cr-labeled target cells prepared as described pre-viously4^At the termination of the culture, 100 (A of the supernatant were removed and the radioactivity was determined by a^-counter. The spontaneous release was determined by incubating 51Crlabeled target cells alone and the maximumrelease was determined by incubating 51Cr-labeled target cells with 0.5 % sodium dodecyl sulfate. The following formula was used to compute percent lysis. Lysis ( %) = 100 x (test cpm-spontaneous cpm)/(maximum cpm-spontaneous cpm)
Metastasis
Lewis lung carcinoma and B1 6 melanoma cells were maintained in vitro, using RPMI-1 640 medium. Cells were detached from culture vessels by trypsin-treatment and suspended in MEM. After washing twice with MEM,1 x 106 cells (Lewis lung carcinoma) or 4 x 105 cells (B16 melanoma) were inoculated through tail vein of BDF1mice. Antimetastatic activity was determined by comparison of lung weights of the ascofuranone-treated mice with the control mice.
Results
Antitumor effect of ascofuranone on syngeneic mammarycarcinoma, FM3A,is shown in Table 1 . Whenmice were implanted with 105 FM3Acells, they died within 30 days after the tumor implantation. Table 1 . Survival time of ascofuranone-treated mice inoculated with FM3A. Treatment with ascofuranone expanded survival time of the mice and some of them survived on day 40. Although ascofuranone was effective both by pretreatment and by posttreatment, more evident effect was obtained by the former. All the mice treated once on day -4 or three times on days -7, -5 and -3 were alive for 40 days.
Treatment (day) None
Ascofuranoneactivates cytotoxic activity of mousesplenocytes in vivoz). Significant activation was observed as early as 24 hours after the treatment and reached maximumlevel on day 4 ( Table 2) . Seven days later, the activation disappeared. Thus, the kinetics of splenic cytotoxic activity were in parallel with that of antitumor activity. Effectors mediating the cytotoxicity in the ascofuranonetreated splenocytes, belonged to the plastic dish-nonadherent population (Table 3) .
Since ascofuranone activates macrophagesin vitro0 , phagocytic activity of ascofuranone-treated mice was assessed by carbon clearance test (Table 4 ). As expected, ascofuranone-treatment significantly activated phagocytic activity in vivo. The activation reached maximumlevel 24 hours after the treatment and disappeared after 7 days. Thus, the activation of phagocytes preceded the expression of antitumor activity or the activation of cytotoxic activity of splenocytes.
In addition, ip treatment with the antibiotic induced phagocytes in the peritoneal cavity which JULY 1988 Peritoneal cells (2 x 105/well) from C3H/He mice were incubated with 51Cr-labeled target cells (5 x 103/well) for 4 hours. Ascofuranone (200 mg/kg) was administered ip on the day indicated. a Mean±SD(n=3). Numbers in parentheses; lysis (%). * P<0.05, ** P<0.005.
are mainly composed of polymorpho-nuclear leukocytes (PMNs) and macrophages ( Table 5 ). Peak of the induction of PMNswas 24 hours after the treatment, while that of macrophages was 4 days after the treatment. PMNsin splenocytes also increased 4 days after the treatment, without affecting the total number of splenocytes. These kinetic studies shown in Tables 1, 2, 3 and 4 were reproducible in several additional experiments. Cytotoxic activity of the peritoneal phagocytes induced by ascofuranone was significantly enhanced ( Table 6 ). The peritoneal cells which were induced 4 days after the treatment, acquired the ability to kill NK-resistant cell lines, FM3Aand P388, as well as a standard NK-sensitive cell line, YAC-1. Effectors mediating the cytotoxicity against NK-resistant and sensitive tumors belonged to the plastic dish-nonadherent population as in the case of splenic cytotoxicity (Table 7) . The cytotoxic activities by 20 hours-assay were also determined because tumoricidal activities mediated by macrophages and PMNs require long term co-culture with target cells6»7). Results were same as in the case of 4 hourassay. Ascofuranone (200 mg/kg) was administered ip to three C3H/He mice. 4 days after the administration, peritoneal cells were pooled and cells (2x 105/well) were cultured on a flat-bottomed microtiter well for 2 hours at 37°C. Nonadherent cells were separated by vigorous pipetting. Residual adherent cells, nonadherent cells and unfractionated cells were further cultured with 51Cr-labeled FM3A cells (5x103/well) and radioactivity in the supernatant was determined after an indicated cultivation.
a Mean±SD (n=3).
The above results imply the role of phagocytes in the antitumor activity of ascofuranone. Therefore, mice treated with ascofuranone 4 days prior to tumor implantation were injected ip with silica immediately before tumor implantation. The result is shown in Table 8 . Four of the five ascofuranone-treated mice survived 80 days after the tumor implantation, whereas all of the tumor bearing mice without treatment died as a result of the tumor incidence.
Silica-treatment com-963 a Mean±SD (n=5). *P<0.05 pletely diminished the prophylactic antitumor activity of ascofuranone, confirming the role of phagocytes in the antitumor activity.
Since activated macrophages and NKcells are possible candidates for suppression of tumor metastasis6>7\ the above results prompted us to study the effect of ascofuranone on tumor metastasis (Table 9 ). Pulmonary metastasis was evaluated by the increase of lung weight. In the case of Lewis lung carcinoma, a single treatment of ascofuranone 4 days before the inoculation significantly suppressed increase of lung weight. Moreremarkable suppression was observed, whenusing B16 melanoma cells. A single treatment 1 day before the inoculation as well as multiple treatment significantly suppressed increase of lung weight. It should be noted that ascofuranone showed no antimetastatic activity against B16 melanomacells by a single treatment 4 days before the inoculation, while the same treatment gave most striking antitimor activity against FM3Aor antimetastatic activity against Lewis lung carcinoma. Posttreatment also showed no metastatic activity, as in the case of Lewis lung carcinoma. Twoadditional experiments showed similar kinetics.
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Discussion
Intraperitoneal treatment with ascofuranone enhances splenic cytotoxic activity and the plausible mediator of the cytotoxicity is suggested to be NKcells3). However, in vitro study shows that the antibiotic inhibits functions of lymphocytes including NKcells, while it activates macrophages4). Here, we showedthat ascofuranone also activates phagocytes in vivo. The intraperitoneal treatment induced inflammatory cells mainly composed of macrophages and PMNs, and these induced peritoneal cells were activated to kill tumor cells nonspecifically. Since NKcells8>9), PMNs10)and macro-phages9>n'12) are important in the protection of host animal from tumor incidence, present results showing significant activation of those cells by ascofuranone are consistent with the prophylactic antitumor activity of the antibiotic.
Activation of splenic and peritoneal cytotoxicity and induction of peritoneal macrophages reached maximumlevel 4 days after the treatment. The kinetic were consistent with that of antitumor activity. On the other hand, maximumactivation of phagocytes, when determined by carbon clearance test, was observed as early as 24 hours after the treatment, suggesting that ascofuranone primarily activates phagocytes, which subsequently enhances cytotoxic activity of the spleen cells or peritoneal cells. Complete abrogation of the antitumor activity by silica treatment, also suggests an essential role of phagocytes in the expression of antitumor activity of ascofuranone.
A time course study demonstrated that the peak of induction of macrophages in the peritoneal cavity was 4 days after the ascofuranone-treatment, whereas that of PMNs was 24 hours after the treatment.
Similar kinetics have been reported with inflammatory agents6»12»13), although the inflammatory cells have no cytotoxic activity without appropriate stimulation of Iectin-treatment6 >7 ' 14' 15) , and such inflammation never induced host-mediated antitumor activity12»13).
Our preliminary experiments suggested that ascofuranone-induced effector cells with cytotoxicity in the peritoneal cavity and spleen were not adherent to the plastic dish. Since ascofuranone-induced peritoneal cells were mainly composedof macrophages and PMNs,the most probable candidates are PMNs.However, induction of PMNs reached a maximumlevel 24 hours after the treatment, whereas that of cytotoxicity 4 days after the treatment. Thus, early induced PMNsmay be qualitatively different from late induced ones. In fact, the latter had more segmented nuclears than the former. Both NKcells and activated macrophages16~20) are important populations which suppress metastasis. As was expected, ascofuranone significantly suppressed pulmonary metastasis of Lewis lung carcinoma and B16melanoma.However,suppressive effect of ascofuranone on these two metastatic models was somewhatdifferent. Metastasis of Lewis lung carcinoma was suppressed only whenascofuranone was administered 4 days before the tumor implantation. On the other hand, that of B16 melanomawas not suppressed by the same treatment, although high efficacy was obtained by the other schedule. Two explanations may be possible. One is difference of the effector population. The other is difference of locus where tumor cells are attacked by effector cells since there has been reported that local activity of effectors is important in the suppression of metastasis18'20).
Although further study is necessary to elucidate the effector population responsible for the suppression of metastasis or cytotoxic activity in the spleen and peritoneal cavity, present results suggest that ascofuranone exhibits its antitumor and antimetastatic activity through activation of phagocytes and subsequent induction of cytotoxic effectors which eliminate tumor cells.
